115 related articles for article (PubMed ID: 9587130)
41. [Multivariate analysis on prognostic factors of non-Hodgkin's lymphoma].
Yong W; Zhang YT; Wei Y
Zhonghua Zhong Liu Za Zhi; 1997 May; 19(3):212-4. PubMed ID: 10920900
[TBL] [Abstract][Full Text] [Related]
42. Long-term outcome of adults with systemic anaplastic large-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte trials.
Sibon D; Fournier M; Brière J; Lamant L; Haioun C; Coiffier B; Bologna S; Morel P; Gabarre J; Hermine O; Sonet A; Gisselbrecht C; Delsol G; Gaulard P; Tilly H
J Clin Oncol; 2012 Nov; 30(32):3939-46. PubMed ID: 23045585
[TBL] [Abstract][Full Text] [Related]
43. [Primary non-Hodgkin's lymphoma of the nasal cavity at early stage: long-term treatment outcomes and prognostic analyses of 108 cases].
He YF; Zhang YJ; Li YH; Lin TY; Xia YF; Lu TX; Huang HQ; Jiang WQ; Xian CG; He YJ; Guan ZZ
Ai Zheng; 2006 Dec; 25(12):1538-42. PubMed ID: 17166382
[TBL] [Abstract][Full Text] [Related]
44. Lomustine (chloroethylnitrosourea [CCNU]), ifosfamide, bleomycin, vincristine, and cisplatin (CIBO-P) is an effective regimen for patients with poor prognostic refractory or multiple disease recurrent aggressive non-Hodgkin lymphoma.
Musolino A; Perrone MA; Michiara M; Delnevo D; Franciosi V; Di Blasio B; Ceci G; Camisa R; Ardizzoni A; Cocconi G
Cancer; 2005 May; 103(10):2109-17. PubMed ID: 15803492
[TBL] [Abstract][Full Text] [Related]
45. [Treatment outcomes and prognostic analyses of relapsed or refractory T-cell non-Hodgkin's lymphoma].
Gao Y; Huang HQ; Lin XB; Cai QQ; Pan ZH; Wang BF; Bu Q
Ai Zheng; 2007 Aug; 26(8):909-13. PubMed ID: 17697558
[TBL] [Abstract][Full Text] [Related]
46. Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte.
Feugier P; Van Hoof A; Sebban C; Solal-Celigny P; Bouabdallah R; Fermé C; Christian B; Lepage E; Tilly H; Morschhauser F; Gaulard P; Salles G; Bosly A; Gisselbrecht C; Reyes F; Coiffier B
J Clin Oncol; 2005 Jun; 23(18):4117-26. PubMed ID: 15867204
[TBL] [Abstract][Full Text] [Related]
47. Antiphospholipid antibodies may be a new prognostic parameter in aggressive non-Hodgkin's lymphoma.
Bairey O; Blickstein D; Monselise Y; Lahav J; Stark P; Prokocimer M; Nativ HM; Kirgner I; Pazgal I; Shaklai M
Eur J Haematol; 2006 May; 76(5):384-91. PubMed ID: 16466368
[TBL] [Abstract][Full Text] [Related]
48. [Treatment of aggressive non-Hodgkin's lymphoma with the ProMACE- CytaBOM protocol].
Mihaljević B; Jancić-Nedeljkov R; Sretenović M; Milivojević G; Janković S; Petrović M
Srp Arh Celok Lek; 1998; 126(9-10):345-8. PubMed ID: 9863405
[TBL] [Abstract][Full Text] [Related]
49. Long-term follow-up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper-CVAD), a dose-intensive regimen, in adult acute lymphocytic leukemia.
Kantarjian H; Thomas D; O'Brien S; Cortes J; Giles F; Jeha S; Bueso-Ramos CE; Pierce S; Shan J; Koller C; Beran M; Keating M; Freireich EJ
Cancer; 2004 Dec; 101(12):2788-801. PubMed ID: 15481055
[TBL] [Abstract][Full Text] [Related]
50. Premature ovarian failure and fertility in long-term survivors of Hodgkin's lymphoma: a European Organisation for Research and Treatment of Cancer Lymphoma Group and Groupe d'Etude des Lymphomes de l'Adulte Cohort Study.
van der Kaaij MA; Heutte N; Meijnders P; Abeilard-Lemoisson E; Spina M; Moser EC; Allgeier A; Meulemans B; Simons AH; Lugtenburg PJ; Aleman BM; Noordijk EM; Fermé C; Thomas J; Stamatoullas A; Fruchart C; Brice P; Gaillard I; Bologna S; Ong F; Eghbali H; Doorduijn JK; Morschhauser F; Sebban C; Roesink JM; Bouteloup M; Van Hoof A; Raemaekers JM; Henry-Amar M; Kluin-Nelemans HC
J Clin Oncol; 2012 Jan; 30(3):291-9. PubMed ID: 22184372
[TBL] [Abstract][Full Text] [Related]
51. Prognostic significance of received relative dose intensity in non-Hodgkin's lymphoma patients: application to LNH-87 protocol. The GELA. (Groupe d'Etude des Lymphomes de l'Adulte).
Lepage E; Gisselbrecht C; Haioun C; Sebban C; Tilly H; Bosly A; Morel P; Herbrecht R; Reyes F; Coiffier B
Ann Oncol; 1993 Sep; 4(8):651-6. PubMed ID: 7694634
[TBL] [Abstract][Full Text] [Related]
52. A predictive model for aggressive non-Hodgkin's lymphoma.
International Non-Hodgkin's Lymphoma Prognostic Factors Project
N Engl J Med; 1993 Sep; 329(14):987-94. PubMed ID: 8141877
[TBL] [Abstract][Full Text] [Related]
53. Prognostic significance of bcl-2 protein expression in aggressive non-Hodgkin's lymphoma. Groupe d'Etude des Lymphomes de l'Adulte (GELA).
Hermine O; Haioun C; Lepage E; d'Agay MF; Briere J; Lavignac C; Fillet G; Salles G; Marolleau JP; Diebold J; Reyas F; Gaulard P
Blood; 1996 Jan; 87(1):265-72. PubMed ID: 8547651
[TBL] [Abstract][Full Text] [Related]
54. Incidence and risk factors of central nervous system relapse in histologically aggressive non-Hodgkin's lymphoma uniformly treated and receiving intrathecal central nervous system prophylaxis: a GELA study on 974 patients. Groupe d'Etudes des Lymphomes de l'Adulte.
Haioun C; Besson C; Lepage E; Thieblemont C; Simon D; Rose C; Tilly H; Sonet A; Lederlin P; Attal M; Brière J; Reyes F
Ann Oncol; 2000 Jun; 11(6):685-90. PubMed ID: 10942056
[TBL] [Abstract][Full Text] [Related]
55. Prognostic significance of survivin expression in diffuse large B-cell lymphomas.
Adida C; Haioun C; Gaulard P; Lepage E; Morel P; Briere J; Dombret H; Reyes F; Diebold J; Gisselbrecht C; Salles G; Altieri DC; Molina TJ
Blood; 2000 Sep; 96(5):1921-5. PubMed ID: 10961895
[TBL] [Abstract][Full Text] [Related]
56. Prognostic factors in inoperable adenocarcinoma of the lung: a multivariate regression analysis of 259 patients.
Sørensen JB; Badsberg JH; Olsen J
Cancer Res; 1989 Oct; 49(20):5748-54. PubMed ID: 2790789
[TBL] [Abstract][Full Text] [Related]
57. [Recent data on the epidemiology of non-Hodgkin lymphoma. Groupe d'Etudes des Lymphomes de l'Adulte (GELA)].
Bosly A; Coiffier B
Pathol Biol (Paris); 1997 Jun; 45(6):449-52. PubMed ID: 9309258
[TBL] [Abstract][Full Text] [Related]
58. Low-grade stage III-IV follicular lymphoma: multivariate analysis of prognostic factors in 484 patients--a study of the groupe d'Etude des lymphomes de l'Adulte.
Decaudin D; Lepage E; Brousse N; Brice P; Harousseau JL; Belhadj K; Tilly H; Michaux L; Chèze S; Coiffier B; Solal-Céligny P
J Clin Oncol; 1999 Aug; 17(8):2499-505. PubMed ID: 10561315
[TBL] [Abstract][Full Text] [Related]
59. Second cancers and late toxicities after treatment of aggressive non-Hodgkin lymphoma with the ACVBP regimen: a GELA cohort study on 2837 patients.
André M; Mounier N; Leleu X; Sonet A; Brice P; Henry-Amar M; Tilly H; Coiffier B; Bosly A; Morel P; Haioun C; Gaulard P; Reyes F; Gisselbrecht C;
Blood; 2004 Feb; 103(4):1222-8. PubMed ID: 14576060
[TBL] [Abstract][Full Text] [Related]
60. Non-Hodgkin's lymphomas: immunologic prognostic studies.
Hadzi-Pecova L; Petrusevska G; Stojanovic A
Prilozi; 2007 Jul; 28(1):39-55. PubMed ID: 17921917
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
